MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Eli Lilly (NYSE: LLY) stock tanked after the company reported third-quarter results on Wednesday, Oct. 30. The report it issued before the opening bell was more than a little problematic.

Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

INDIANAPOLIS — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker on Wednesday ...

Eli Lilly (NYSE:LLY) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk (NVO) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials ...

See more Insider Deals here. Your lifetime productivity buddy — Microsoft Office 2021 you'll pay for only once Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker on Wednesday chopped a ...